DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for T-Cell Prolymphocytic Leukemia — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleT-Cell Prolymphocytic Leukemia maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedDasatinibApproved drug
Structures already discussed alongside t-cell prolymphocytic leukemia in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of EphA4 kinase domain — Dasatinib has a real, experimentally solved structure in complex with this target (PDB 2Y6O, 1.543 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet 1n1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2Y6O · 1.543 Å · ligand Dasatinib (1N1). Experimental structure, not a prediction.
What the evidence adds up to
T-cell prolymphocytic leukemia is a rare mature T-cell malignancy with an aggressive clinical course. The disease typically presents with rapidly rising lymphocyte counts in peripheral blood, splenomegaly, bone marrow involvement, and often skin lesions. Lymphocytosis can exceed 100×10⁹/L. The clinical behaviour is consistently described as highly aggressive across multiple reports from 2002 to 2020.
Response to conventional chemotherapy is poor. Median survival times from diagnosis are usually under two to three years. As of 2019, no drug had received FDA or EMA approval for this indication. The only potential long-term curative treatment remains haematopoietic stem cell transplantation. One case report from 2002 describes an 84-year-old man whose first manifestation was a non-specific cutaneous rash, and the 2005 report of a small cell variant likewise notes that treatment is difficult.
The differential diagnosis is broad and includes other T-cell disorders with overlapping clinical findings. The entity is distinguished from chronic lymphocytic leukaemia by its post-thymic origin and distinct cytogenetic features. What remains missing is any randomised trial data, a funded drug development programme for this orphan disease, and reliable patient stratification beyond the recognition that standard chemotherapy is ineffective.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Baylor University Medical Center Proceedings · 2013 · 21 citations · open access
T-Cell Prolymphocytic Leukemia
AbstractT-cell prolymphocytic leukemia is a rare and unusual malignancy characterized by the proliferation of small- to medium-sized prolymphocytes of postthymic origin with distinctive clinical, morphologic, immunophenotypic, and cytogenetic features. Involvement of the peripheral blood, bone marrow, lymph nodes, liver, spleen, and skin can occur. The clinical course is typically very aggressive with poor response to conventional chemotherapy and short survival rates, and the only potential long-term curative treatment is hematopoietic stem cell transplantation. We report the case of a man with de novo T-cell prolymphocytic leukemia and discuss the distinctive clinical, morphologic, immunophenotypic, and cytogenetic features of this entity.
AbstractT-cell prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia typically presenting at stages of exponentially rising lymphocyte counts in peripheral blood, accompanied by splenomegaly and bone marrow involvement T-PLL is inherently highly aggressive and its notoriously refractory behavior to conventional therapeutics Median survival times from diagnosis are usually under 2-3 years. Up until now there is not a single FDA or EMA
International Journal of Laboratory Hematology · 2020 · 6 citations
T‐cell prolymphocytic leukemia: Review of an entity and its differential diagnostic considerations
AbstractT-cell prolymphocytic leukemia (T-PLL) is a rare T-cell leukemia characterized in many patients by marked peripheral lymphocytosis, prominent splenomegaly, and skin lesions. The differential diagnosis is broad and includes other T-cell disorders presenting with similar clinical findings. This review addresses (a) the natural history, demographics, and genetic features of T-PLL; (b) clinical and pathologic differential diagnostic considerations; and (c) recent developments in the T-PLL literature relevant to laboratory professionals.
Anales de Medicina Interna · 2002 · 1 citations · open access
Erupción cutánea eritematosa como primera manifestación de leucemia linfática prolinfocítica de células T
AbstractWe present a case of a man 84 years-old, whose presentation feature was a cutaneous inespecific rash, and was diagnosed of T prolymphocytic leukaemia (T-PLL). In this review we analyze actual aspects concerning biology, diagnosis, classification, prognosis and treatment of this rare mature T cell leukaemia.
The Korean Journal of Hematology · 2005 · 1 citations · open access
A Case of Small Cell Variant of T-Cell Prolymphocytic Leukemia
AbstractT-cell prolymphocytic leukemia (T-PLL) is a post-thymic T-cell malignancy that has an aggressive clinical course and it is a distinct clinico-biological entity from other T-cell disorders.It is now apparent that this disease represents a separate entity from CLL. Clinically, T-PLL presents with hepatosplenomegaly, lymphadenopathy, skin lesion, and marked lymphocytosis exceeding 100×10 9 /L.Because its clinical course is aggressive, the treatment is difficult.We report a case of small cell variant of T-cell with a review of literatures.(
Expert Opinion on Orphan Drugs · 2015 · 0 citations
Dasatinib for acute lymphoblastic leukemia
AbstractIntroduction: Despite considerable improvement in the prognosis of Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in the era of tyrosine-kinase inhibitors (TKI), less than half of the patients can be cured. Among several TKI now available, dasatinib (SPRYCEL®) displays theoretical advantages and a robust clinical experience.Areas covered: After an overview of Ph+ ALL current and future therapies, this article presents the chemistry, pharmacodynamics and pharmacokinetics of dasatinib, shedding light on mechanisms of action, resistance and toxicity. Clinical efficacy and tolerability of the drug, alone or in combination with chemotherapy and/or hematopoietic stem cell transplantation, are detailed in phase I and II trials, and in one phase III trial dedicated to dose optimization, in the absence of direct comparative studies between various TKI. A potential role for dasatinib in other subsets of ALL is discussed.Expert opinion: Dasatinib displays an interesting tolerance/efficacy profile in ALL; rates of hematologic and molecular remission of 90% and 35% respectively; disease-free survival at 3 years of 25% to 70% and rare cardio-vascular events; its drawbacks include pleural effusions, risk of hemorrhage and the selection of resistant clones. The main competitors are represented by other drugs targeting the BCR-ABL kinase, such as ponatinib and allosteric inhibitors, and by the growing field of immunotherapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
